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Viral evasion of T cell immunity: ancient mechanisms offering
new applications
Danie¨lle Horst1,2,a, Marieke C Verweij1,a, Andrew J Davison3,
Maaike E Ressing1,2 and Emmanuel JHJ Wiertz1,2Upon infecting a host, viruses are confronted by a coordinated
and multi-faceted immune response. Indeed, evolutionary
combat between virus and host has contributed signally to the
host’s development of a formidable innate and adaptive
immune defense arsenal, and to the virus’ acquisition of
effective means to evade it. Cytotoxic T lymphocytes play a key
role in the elimination of virus-infected cells, which they detect
through recognition of virus-derived peptides displayed at the
cell surface in the context of MHC class I molecules. This highly
sensitive recognition system is a prime target for immune
evasion strategies deployed by many viruses, particularly large
DNA viruses such as herpesviruses and poxviruses. Elucidation
of the mode of action of the immune evasion proteins encoded
by these viruses has not only provided new insights into viral
pathogenesis, but has also led to the discovery of hitherto
unknown cell biological and immunological phenomena.
Moreover, viral immune evasion proteins constitute extremely
useful tools to block defined stages of the MHC class I
presentation pathway, not only for research purposes, but also
for clinical applications.
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Introduction
Cytotoxic T lymphocytes (CTLs) play an important role
in the elimination of virus-infected cells, which they
recognize through the detection of virus-derived peptides
presented at the cell surface by MHC class I (MHC I)
molecules. The viral peptides result from proteasomal
degradation of proteins in the cytosol and are translocated
Open access under the Elsevier OA license. Current Opinion in Immunology 2011, 23:96–103by the Transporter associated with Antigen Processing
(TAP) into the endoplasmic reticulum (ER), where they
are loaded onto newly synthesized MHC I molecules. As
an alternative to presentation of peptides derived from
endogenously synthesized proteins, specialized antigen
presenting cells, such as dendritic cells, may take up viral
proteins from their environment and present peptides
derived from those proteins to CTLs. This process of
presenting exogenous antigens via MHC I molecules is
known as cross-presentation; the routes by which exogen-
ous antigens reach MHC I molecules are poorly under-
stood. As will be discussed, viral inhibitors of antigen
presentation are powerful instruments to decipher the
routing of antigens in both direct and cross-presentation.
DNA viruses with a large genome coding capacity, such as
herpesviruses, have proven particularly adept at prevent-
ing CTL recognition through the actions of dedicated
immune evasion proteins. The family Herpesviridae,
which is divided into the subfamilies Alphaherpesvirinae,
Betaherpesvirinae, and Gammaherpesvirinae (whose mem-
bers are often referred to as alphaherpesviruses, betaher-
pesviruses, and gammaherpesviruses, respectively), is
estimated to have emerged roughly 400 million years
ago [1]. The long co-evolution of these viruses with their
host is believed to have contributed to extensive adap-
tation of these pathogens to their respective hosts.
The vast majority of the human population is infected
with one or more of the eight known human herpes-
viruses, namely herpes simplex viruses types 1 and 2
(HSV-1 and HSV-2), varicella-zoster virus (VZV), human
cytomegalovirus (HCMV), human herpesviruses 6 and 7
(HHV-6 and HHV-7), Epstein-Barr virus (EBV), and
Kaposi’s sarcoma-associated herpesvirus (KSHV) [2].
Herpesvirus infections usually cause only mild symp-
toms, but serious complications can arise, particularly
in immunocompromised individuals. In addition, HCMV
is the most common viral cause of congenital defects, and
EBV and KSHV are associated with the development of
several malignancies [3].
A hallmark of herpesviruses is their ability to establish
lifelong infections despite the presence of a powerful
immune response directed against these viruses. In
addition, re-infections of immune individuals may occur,
even by the same viral strain. These examples indicate
that herpesviruses have acquired powerful immune eva-
sion mechanisms. Evasion indeed occurs at multiplewww.sciencedirect.com
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immune response. Herpesviruses have been found to
affect antiviral host responses by interfering with cyto-
kine and chemokine signaling [4], by impairing the
complement cascade [5], by preventing natural killer
cell-mediated recognition and elimination of infected
cells [6], and by inhibiting innate immune signaling by
pattern-recognition receptors, such as Toll-like receptors
and RIG-I-like receptors [7]. Furthermore, the past dec-
ades have witnessed the elucidation of diverse strategies
by which herpesviruses manipulate the host adaptive
immune response [8,9]. These include utilizing herpes-
virus-encoded Fc receptors to inhibit antibody-mediated
effector mechanisms [10] and subverting the MHC II [11]
and, particularly, the MHC I antigen processing and
presentation pathways.
Herpesviruses encode a wealth of proteins specifically
interfering with MHC I-restricted antigen presentation.
More recently, also poxviruses have been found to
actively evade MHC I-restricted CTLs through a series
of specialized gene products. The characteristics of these
immune evasion proteins, their deployment during evol-
utionary combat, their remarkably distinct mechanisms of
action, and their application as versatile tools in antigen
presentation studies are discussed in this review.
The MHC I antigen presentation pathway is a
prime target for viral immune evasion
Herpesvirus immune evasion strategies appear to target
each step of the MHC I presentation pathway (Figure 1).
The gammaherpesviruses EBV and KSHV encode the
latency-associated proteins EBNA1 and LANA, respect-
ively, which interfere with their own translation and with
their proteasomal degradation, thereby reducing the
generation of antigenic peptides [12,13,41]. Alphaherpes-
viruses and gammaherpesviruses express shutoff proteins
that block host protein synthesis, with new MHC I
molecules being among the host proteins that are affected
[14–18]. The Viral Inhibitor of Heavy Chain Expression
or VIHCE protein of rhesus CMV (RhCMV) specifically
inhibits the synthesis of MHC I heavy chains in a signal
peptide-dependent fashion through a yet enigmatic
mechanism [19].
Levels of MHC I molecules are also targeted in a more
selective fashion, for example by the HCMV-encoded
proteins US2, US10, and US11 [20–22], mouse cytome-
galovirus (MCMV) glycoprotein (gp) 48, and murine
gammaherpesvirus 68 (MHV68) mK3, which accelerate
the degradation of MHC I molecules [8,9,23]. An alterna-
tive strategy to reduce display of peptide-presenting
MHC I complexes at the surface of infected cells involves
intracellular retention (by HCMV US3 and MCMV gp40)
or increased endocytosis (by KSHV kK3/kK5 and
EBV BILF1) [8,9,23]. At the cell surface, MCMV gp34
interferes with recognition of peptide-loaded MHC Iwww.sciencedirect.comcomplexes by cytotoxic T cells [23]. Finally, many her-
pesviruses encode proteins that specifically block ER
import of antigenic peptides by TAP. As will be discussed
below, this class of immune evasion proteins demon-
strates an unexpected diversity, both in structure and
mode of action. Recently, also cowpox virus has been
found to encode molecules specifically eluding MHC I-
restricted CTL recognition. The CPX V203 protein
interferes with intracellular trafficking of MHC I mol-
ecules by sequestering them in the ER [24]. CPX V012
prevents peptide transport by TAP, thereby representing
the first TAP inhibitor outside the herpesvirus family
[25,26,27].
The expanding repertoire of viral evasion molecules not
only creates a valuable toolbox for immunological studies,
but also reveals new insights into normal functions of the
cell and the immune system in particular.
Viral immune evasion: lessons in immunology
and cell biology
Research into the mechanisms underlying viral evasion
strategies has led to the discovery of previously unknown
cellular processes. This is illustrated by the HCMV
proteins US2 and US11, which target MHC I molecules
for proteasomal degradation [20,21]. The MHC I heavy
chains (HC) are properly translocated into the ER, as
inferred from their N-linked glycosylation, but sub-
sequently are redirected to the cytosol, where they are
degraded through the ubiquitin–proteasome pathway.
The retrograde movement of the MHC I HC, termed
‘dislocation’ (as opposed to translocation), appears to
occur via a constitutive pathway in the cell that plays a
role in many important cellular processes, including
protein quality control, the release of proteins from the
ER in the context of the Unfolded Protein Response
(UPR) [28], and also antigen (cross-)presentation (dis-
cussed below). The US2 and US11-mediated dislocation
of MHC I HC serves as a paradigm of ER protein
dislocation and degradation and has facilitated the charac-
terization of many features of this process. These include
the involvement of the translocon or Sec61 complex as a
channel mediating transport of at least certain categories
of dislocation substrates [20], the role of the proteasome–
ubiquitin system, and the discovery of hitherto unknown
constituents of this protein degradation pathway, among
which the AAA ATPase p97, members of the derlin
family, and ER-resident ubiquitin E3 ligases [28,29].
Recent studies indicate that protein dislocation plays a
role in antigen presentation as well, allowing proteins to
migrate from intracellular compartments, such as phago-
somes, and the secretory pathway back to the cytosol,
where they are degraded into peptides by the proteasome
[30,31,32,33]. The peptides derived from dislocated
ER proteins are re-imported into the ER by TAP for
MHC I-restricted presentation. Additionally, TAPCurrent Opinion in Immunology 2011, 23:96–103
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facilitating translocation of peptides into those compart-
ments for (cross-)presentation by MHC I molecules
[30,31,34]. In a number of studies, dislocation of
proteins was found to involve the Sec61 complex, analo-
gous to HCMV US2 and US11-mediated retrotransloca-
tion of MHC I HC [30,31,33].
The role of the dislocation pathway in antigen processing
is further illustrated by tyrosinase, a melanocyte differ-
entiation protein that is a target for melanoma-reactive T
cells [35]. Glycoproteins that are dislocated from the ER
back to the cytosol lose their N-linked glycans in a
reaction that is catalyzed by a cytoplasmic N-glycanase.
This deglycosylation involves the deamidation of aspar-
agines, changing these amino acids into aspartic acid. The
presence of an aspartic acid residue within a T cell
epitope of tyrosinase at a position where the native
protein carries an asparagine residue witnesses the invol-
vement of the cytosolic N-glycanase, and thus ER-to-
cytosol dislocation, as an essential step in the processing
of this particular epitope [36]. Deamidation has been
found for several other T cell epitopes, including epitopes
derived from HIV-1 env, hepatitis C virus E1, and lym-
phocytic choriomeningitis virus (LCMV) GP1 [36],
suggesting a wide role for protein dislocation in antigen
presentation.
Another important cellular process that is manipulated by
viruses in many ways is the ubiquitin system. Herpes-
viruses code for E3 ubiquitin ligases, such as HSV ICP0,
KSHV kK3 and kK5, and MHV68 mK3, but also for
numerous de-ubiquitinating enzymes. The intriguing
interplay between viruses and the ubiquitin system has
been reviewed by Isaacson and Ploegh [37]. An example
of an interesting, novel phenomenon discovered in the
context of herpesvirus immune evasion pertains to ubi-
quitin conjugation by the E3 ligases mK3 and kK3/kK5 of
MHV68 and KSHV, respectively. These proteins catalyze
the ubiquitination of cytoplasmic domains of MHC I HC,
resulting in the proteasomal degradation (in case of
MHV68) or endocytosis (in case of KSHV) of MHC I
molecules [8]. When the amino acid residues that are
ubiquitinated were identified within the MHC I HC, it
was found that in addition to the common ubiquitin
acceptor lysine, also cysteine, serine, and threonine resi-
dues were ubiquitinated [38,39,40]. These findings
implicate a novel chemical mechanism of substrate ubi-
quitination via ester linkages. Most probably, cysteine,
serine, and threonine ubiquitination is used more widely
by the cell. The functional implications of this particular
type of conjugation are yet to be determined.
Viral immune evasion proteins: valuable tools
in antigen presentation studies
EBV EBNA1 and KSHV LANA carry large repeats of
glycine-alanine and serine-proline residues, respectively,www.sciencedirect.comthat hamper proteasomal degradation of these viral gene
products [13,41]. When transferred to other proteins, the
repeats effectively block degradation of these proteins in
cis. Thus, they can be used to inhibit the first stage of the
MHC I presentation pathway, namely the generation of
antigenic peptides by proteasomes [41,42]. EBNA1 has
also been instrumental in uncovering the role of autop-
hagy in antigen presentation. Using EBNA1 as a model
antigen, autophagy was found to allow MHC II-mediated
presentation of peptides derived from a nuclear or cyto-
solic protein [43,44].
Herpesvirus-encoded TAP inhibitors have been particu-
larly useful in cross-presentation studies aiming to unra-
vel the routes by which exogenous antigens are loaded
onto MHC I molecules. A 35-residue peptide encom-
passing the TAP-inhibiting domain of HSV ICP47 has
been shown to be endocytosed and to subsequently block
TAP function [31]. Since ICP47 interferes with the
binding of peptides to cytosolic domains of TAP, this
finding implies that extracellular proteins can reach the
cytosol of cells, possibly via the Sec61 dislocation pathway
(discussed above) [30,45]. The ICP47 peptide inhibits
both direct and cross-presentation, implicating the invol-
vement of TAP in cross-presentation.
HCMV US6 inhibits TAP by interacting with ER-luminal
domains of TAP. Exposure of DCs to a soluble form of
US6 completely abrogates cross-presentation, confirming
the essential role for TAP in cross-presentation [34,46].
At the same time, these experiments show the existence
of a connection between the extracellular milieu and
TAP-containing compartments and illustrate the contri-
bution of phagosomes and pinosomes to presentation of
exogenous antigens by DCs. Selective deposition of US6
into early endosomes using a US6-transferrin fusion
protein identified these endosomes as loading compart-
ments for cross-presented peptides derived from soluble
antigens [32].
The herpesvirus-encoded TAP inhibitors each act in a
unique way, targeting different stages of the peptide
translocation cycle (summarized in Table 1). ICP47
and EBV-encoded BNLF2a block binding of substrates
to the cytosolic peptide binding site of TAP; US6,
BNLF2a, and the UL49.5 proteins of equine herpesvirus
1 and 4 affect the association of ATP with the nucleotide
binding domains of TAP; US6 and the UL49.5 proteins of
all TAP-inhibiting varicelloviruses interfere with confor-
mational transitions required for translocation of peptides
over the ER membrane, and UL49.5 of bovine herpes-
virus 1 and related ruminant varicelloviruses target TAP
for proteasomal degradation [47–54,55]. Recently, the
cowpox protein CPX V012 was identified as a TAP
inhibitor [25,26]. The mechanism by which this
protein blocks TAP-mediated peptide transport has not
yet been resolved.Current Opinion in Immunology 2011, 23:96–103
100 Antigen processing
Table 1
Comparison of the mechanisms by which virus-encoded proteins specifically interfere with TAP-mediated peptide transport
Virus Inhibitor Structural features Mechanism of TAP inhibition Refs.
HSV-1/2 ICP47 Cytosolic protein Interference with peptide binding [47,48]
BHV-1 UL49.5 Type I membrane protein Conformational alterations and degradation of TAP1/2 [54,55]
EHV-1/4 UL49.5 Type I membrane protein Conformational alterations and interference with ATP binding [54,55]
PRV UL49.5 Type I membrane protein Conformational alterations [54,55]
HCMV US6 Type I membrane protein Conformational alterations and interference with ATP binding [49–51]
EBV BNLF2a Tail-anchored protein Interference with ATP and peptide binding [52,53]
CPX V012 Type II membrane protein Unknown [25,26]The viral TAP inhibitors can be used to block the peptide
translocation cycle at different stages and therefore are
valuable tools to study the molecular biophysics of pep-
tide translocation by TAP. In addition, viral TAP inhibi-
tors may be used to freeze TAP at intermediate stages of
the translocation cycle, which may be informative when
resolving the crystal structure of the peptide transporter
[56,57]. Elucidation of the molecular mechanisms under-
lying viral TAP inhibition will facilitate the use of TAP
inhibitors for selective immune suppression in the con-
text of, for example, auto-immune diseases and tissue and
organ transplantation. In addition, this knowledge may
aid the development of substances blocking other ABC
transporters, for example those responsible for multiple
drug resistance in bacterial and cancer cells.
In vivo implications of viral stealth technology
Recently, several interesting studies have highlighted the
importance of viral immune evasion mechanisms in the
life cycle of viruses in vivo. In addition, animal studies
have been initiated to explore the applications of viral
immune evasion proteins for the rational design of novel
strategies for vaccine development, cancer treatment,
transplant protection, and gene therapy.
Using RhCMV as a model, Hansen et al. have shown that
the evasion molecules encoded by the US region of this
virus (e.g. US2, US3, US6, and US11) are dispensable for
primary infection and persistence of the virus, but are
essential for superinfection of a CMV-immune host
[58]. The in vivo relevance of viral T cell immune
evasion proteins has been demonstrated for two other
viruses as well, namely cowpox virus and MHV68. An
elegant study by Byun and colleagues demonstrated the
biological function of two cowpox virus-encoded inhibi-
tors of MHC I-restricted antigen presentation, CPX V012
and CPX V203 [25]. Deletion of the genes encoding
these evasion proteins restored MHC I surface expression
and T cell stimulation in vitro and reduced virulence in
mice, thus demonstrating the significance of these
immune evasion proteins in one of the virus’ natural host
species. For MHV68, deletion of the MHC I inhibitor
mK3 increased CTL responses to lytic viral proteins,
without major effects on viral replication. By contrast,
removal of mK3 resulted in decreased latent viral loads,Current Opinion in Immunology 2011, 23:96–103suggesting a role for immune evasion in amplifying the
latent reservoir for this herpesvirus [59].
The capacity of herpesviruses to superinfect immune
hosts, and to induce and maintain strong T cell immunity
makes these viruses promising vaccine vectors. The
potential of this approach has been demonstrated in a
landmark study by Hansen et al., who used RhCMV as a
carrier virus for immunization against simian immunode-
ficiency virus infection [60].
Alternative applications of viral stealth technology in the
fields of transplant protection and cancer therapy have
been reviewed by Horst et al. [61]. An interesting
example is the use of viral TAP inhibitors to induce T
cells recognizing an alternative peptide repertoire carried
by tumor cells with antigen processing defects [62].
MHC I molecules of tumor cells with deficiencies in the
MHC I presentation pathway carry a repertoire of sub-
dominant T cell epitopes, named T cell Epitopes associ-
ated with Impaired Peptide Processing (TEIPP). T cells
directed against TEIPP can be selected in vitro using
antigen presenting cells expressing viral TAP inhibitors
such as the bovine herpesvirus 1 UL49.5 protein. These
TEIPP-specific T cells protect mice against the out-
growth of TAP-deficient lymphomas and fibrosarcomas
[63].
Viral stealth technology also holds promise in gene
therapy, providing tools to improve the survival of cells
expressing a transgene, which often represents a neo-
antigen (reviewed by Horst et al.) [61].
Conclusions
Large DNA viruses, such as herpesviruses and pox-
viruses, dedicate a considerable part of their genome to
immune evasion. The MHC I antigen processing and
presentation pathway appears to be a prime target for viral
evasion, illustrating the evolutionary pressure exerted by
CD8+ CTLs during co-evolution of these viruses with
their hosts. Viral immune evasion proteins target virtually
every step in the MHC I pathway and therefore constitute
powerful tools for antigen processing and presentation
research. The power of this approach has been demon-
strated in studies in which TAP inhibitors have been usedwww.sciencedirect.com
Viral evasion of T cell immunity: ancient mechanisms offering new applications Horst et al. 101to uncover important, basic features of cross-presentation.
Elucidation of the mechanisms underlying viral immune
evasion strategies reveals essential, hitherto unknown cell
biological and immunological processes that have been
discovered by viruses as effective targets for immune
evasion millions of years ago.
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